Literature DB >> 26998294

Skin rash in the intensive care unit: Stevens-Johnson syndrome, toxic epidermal necrolysis, or a rare manifestation of a hidden cutaneous malignancy: A case report.

Farah Al-Saffar1, Saif Ibrahim1, Pujan Patel1, Rafik Jacob1, Carlos Palacio1, James Cury2.   

Abstract

Skin rashes are infrequently encountered in the intensive care units, either as a result or as a cause of admission. The entities of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) form a spectrum of desquamating skin diseases that have multiple etiologies, the most common being drug-related reactions; very rarely, the cause may be cutaneous malignancies. We herein present a unique case of a 54-year-old male patient with psoriasis treated with methotrexate, who presented with a cellulitis-like clinical picture, then developed a severe progressive systemic inflammatory response syndrome, and progressed clinically to SJS, then TEN even after discontinuing the antibiotics and methotrexate. A skin biopsy demonstrated an aggressive and rapidly-progressing T-cell lymphoma. The present case highlights the necessity of skin biopsy when encountering SJS and TEN in the ICU in order to identify potentially treatable/controllable causes. Although it appeared reasonable to correlate TEN solely to medications, the skin biopsies clearly demonstrated an aggressive T-cell skin lymphoma. In a patient with a better general condition it may have been helpful to treat this malignancy. TEN is a life-threatening condition and skin biopsy is the cornerstone of diagnosis, despite the presence of multiple risk factors and the typical physical findings of a drug-induced reaction.

Entities:  

Keywords:  Stevens-Johnson syndrome; cutaneous lymphoma; lymphoma; toxic epidermal necrolysis

Year:  2015        PMID: 26998294      PMCID: PMC4774480          DOI: 10.3892/mco.2015.713

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  18 in total

1.  Stevens-Johnson syndrome due to prophylactic fluconazole in two patients with liver failure.

Authors:  E Craythorne; D Creamer
Journal:  Clin Exp Dermatol       Date:  2009-06-22       Impact factor: 3.470

2.  Fluconazole-induced Stevens-Johnson syndrome in a HIV-negative patient.

Authors:  Alexandra Monastirli; Efi Pasmatzi; Eleftheria Vryzaki; Sophia Georgiou; Dionysios Tsambaos
Journal:  Acta Derm Venereol       Date:  2008       Impact factor: 4.437

3.  [Stevens-Johnson syndrome and Hodgkin's disease: A fortuitous association or paraneoplastic syndrome?].

Authors:  A Schoeffler; E Levy; M Weinborn; J-F Cuny; J-L Schmutz; A Barbaud; B Cribier; A-C Bursztejn
Journal:  Ann Dermatol Venereol       Date:  2013-12-12       Impact factor: 0.777

Review 4.  Toxic epidermal necrolysis in a neonate receiving fluconazole.

Authors:  S Islam; M Singer; J A Kulhanjian
Journal:  J Perinatol       Date:  2014-10       Impact factor: 2.521

5.  Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma.

Authors:  Brad Jones; Yin Vun; Muna Sabah; Conleth A Egan
Journal:  Australas J Dermatol       Date:  2005-08       Impact factor: 2.875

6.  An autopsy case of malignant lymphoma with Lyell's syndrome.

Authors:  A M Sadi; T Toda; M Kiyuna; T Tamamoto; K Ohshiro; R Shinzato
Journal:  J Dermatol       Date:  1995-08       Impact factor: 4.005

7.  Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem.

Authors:  Amanda Lam; Inderpal Randhawa; William Klaustermeyer
Journal:  Allergol Int       Date:  2008-07-01       Impact factor: 5.836

8.  Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection.

Authors:  A Azón-Masoliver; J Vilaplana
Journal:  Dermatology       Date:  1993       Impact factor: 5.366

9.  Stevens-Johnson syndrome presenting as intravenous line sepsis.

Authors:  S Cheriyan; R M Rosa; R Patterson
Journal:  Allergy Proc       Date:  1995 Mar-Apr

10.  Toxic epidermal necrolysis caused by fluconazole in a patient with human immunodeficiency virus infection.

Authors:  Jacob George; Arun Sharma; Ramakant Dixit; Naveen Chhabra; Smita Sharma
Journal:  J Pharmacol Pharmacother       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.